Napredna pretraga

Pregled bibliografske jedinice broj: 881139

In vitro interaction of pentadecapeptide BPC 157 with standard antibiotics against ATCC strains


Talapko, Jasminka; Drenjančević, Domagoj; Tomić Paradžik, Maja; Sikirić, Predrag;
In vitro interaction of pentadecapeptide BPC 157 with standard antibiotics against ATCC strains // Knjiga sažetaka 7. HRVATSKI KONGRES LABORATORIJSKE DIJAGNOSTIKE (s međunarodnim sudjelovanjem)/Book of Abstracts from 7th CROATIAN CONGRESS OF LABORATORY DIAGNOSTICS (with international participation)
Zagreb, Hrvatska, 2017. str. 17-17 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
In vitro interaction of pentadecapeptide BPC 157 with standard antibiotics against ATCC strains

Autori
Talapko, Jasminka ; Drenjančević, Domagoj ; Tomić Paradžik, Maja ; Sikirić, Predrag ;

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Knjiga sažetaka 7. HRVATSKI KONGRES LABORATORIJSKE DIJAGNOSTIKE (s međunarodnim sudjelovanjem)/Book of Abstracts from 7th CROATIAN CONGRESS OF LABORATORY DIAGNOSTICS (with international participation) / - , 2017, 17-17

Skup
IUPHAR GI Section Symposium on Drug Development and New Frontiers in Gastrointestinal Diseases

Mjesto i datum
Zagreb, Hrvatska, 8.-10. 06. 2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Pentadecapeptide BPC 157 ; in vitro assay ; antibacterial activity ; ATCC strains

Sažetak
Introduction: The aim of this research is to examine an in vitro antibacterial activity of pentadecapeptide BPC 157 (BPC 157) on American type culture collection (ATCC) bacterial strains and synergistic action of BPC 157 with standard antibiotics as well. Materials and Methods: In this study BPC 157, manufactured by Diagen Ltd, Ljubljana, Slovenia, 99% purity which was dissolved in saline solution and prepared in concentration of 512 μg/ml, was used. The minimum inhibitory concentration (MIC) according to the Clinical Laboratorz Institute Standards (CLSI) recommendations was determined for all bacterial strain studied: Staphylococcus aureus 25923, Enterococcus faecalis 29212, Pseudomonas aeruginosa 27853, Escherichia coli 25922, Acinetobacter baumanii 19606 and Klebsiella pneumoniae 700803. Beta- lactam, glycopeptide, aminoglycoside, macrolide and quinolone antibiotics were used: for Gram positive strains ampicilin, erythromycin, gentamicin, vancomycin were used while amikacin, ceftazidime, ciprofloxacin and imipenem were tested for Gram negative strains. The interactions of BPC 157 and selected antibiotics were tested by the broth microdilution method. Briefly, the MIC for the selected antibiotics alone and with the addition of fixed concentrations of 512 μg/ml BPC 157 were determined. Statistical analysis was done by Friedman and Wilcoxon test. Results: There is no antibacterial activity of BPC 157 detected and the MIC were above 256 μg/ml for all ATCC strains tested. Sensitivity of ATCC strains on BPC 157 observed by microdilution method and determination of the synergistic/antagonistic activity of BPC 157 with standard antibiotics revealed no statistically significant difference (p> 0.950). Conclusion: According to results from our study we can conclude that BPC 157 doesn’t have direct antibacterial activity in vitro. Synergistic or antagonistic effects between BPC 157 and selected antibiotics tested by microdilution method were not detected for all tested concentrations of BPC 157 and for all bacterial ATCC strains used.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Medicinski fakultet, Zagreb,
Klinički bolnički centar Osijek,
Medicinski fakultet, Osijek